Form 4: Enliven Therapeutics Director Acquires Stock Options

Director Richard A. Heyman acquires stock options in Enliven Therapeutics, Inc.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc. (ELVN), acquired stock options on February 6, 2025.
• The stock options grant the right to buy 23,014 shares of common stock at an exercise price of $22.47.
• The options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon continued service as a non-employee director.
• Following the transaction, Heyman directly owns 23,014 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The grant itself can be seen as a slightly positive sign of alignment between management and shareholders.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, director, Enliven Therapeutics, ELVN, Form 4, beneficial ownership, Richard A. Heyman